BIOMARKERS FOR TREATING CANCER USING MDM2 ANTAGONISTS

• Main Authors: FERRARI NICOLAS, AHN JOHN S, SAINI HRISHIKESH K
• Format: Patent
• Language: Chinese; English
• Published: 30.05.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

The present invention provides SKP2 as a biomarker for predicting an effective treatment of cancer using an MDM2 antagonist. Identifying this biomarker in a cancer patient can determine whether the patient's cancer is likely to be successfully treated with an MDM2 antagonist. Thus, the present invention relates generally to companion diagnostics for MDM2 antagonist therapy. The SKP2 biomarker may be measured directly or indirectly by detecting molecules functionally upstream or downstream of SKP2 and whose levels are associated with the levels of the SKP2 biomarker (e.g., detecting one or more SKP2 substrates). 本发明提供SKP2作为使用MDM2拮抗剂预测癌症有效治疗的生物标志物。在癌症患者中鉴定该生物标志物可以确定患者的癌症是否可能使用MDM2拮抗剂成功治疗。因此，本发明总体上涉及用于MDM2拮抗剂治疗的伴随诊断。SKP2生物标志物可通过检测功能上位于SKP2上游或下游且其水平与SKP2生物标记物水平相关的分子(例如检测一种或多种SKP2底物)直接或间接测量。